Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, for presbyopia as an alternative to reading glasses. Presbyopia is the gradual loss of your eye’s ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide. Orasis is led by a collaborative team of industry executives, Optometrists and Ophthalmologists with a diverse set of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development.